199 related articles for article (PubMed ID: 32027286)
1. [Efficacy of BMMSCs on aGVHD and Its Correlation with SerumInflammatory Cytokines in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host Disease].
Guo SY; Qiu KY; Tang XK; Huang K; Xu HG; Li Y; Weng WJ; Xu LH; Fang JP; Zhou DH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):255-261. PubMed ID: 32027286
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between serum levels of IL-18 and acute graft versus host disease in patients after allogeneic hematopoietic stem cell transplantation].
Liu J; Zhang XG; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):553-7. PubMed ID: 17605864
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of anti-human T cell porcine immunoglobulin with recombinant human tumor necrosis factor-α receptor II: IgG Fc in the treatment of 35 cases of grade III/IV acute graft-versus-host disease after allo-HSCT].
Liu DY; Yan S; Ma DD; Zhang C; Fu KB; Liu XM; Liu XH; Wang Y; Li XQ; Zhang JQ; Xiu YY; Peng XJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):743-748. PubMed ID: 33113606
[No Abstract] [Full Text] [Related]
6. [Clinical observation of mesenchymal stem cell as salvage treatment for refractory acute graft-versus-host disease].
Zhao K; Huang F; Peng YW; Zhou HS; Fan ZP; Zhang X; Guo XT; Xu N; Sun J; Xiang P; Liu QF
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):122-6. PubMed ID: 23611218
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease.
Sakata N; Yasui M; Okamura T; Inoue M; Yumura-Yagi K; Kawa K
Bone Marrow Transplant; 2001 Jun; 27(11):1153-61. PubMed ID: 11551026
[TBL] [Abstract][Full Text] [Related]
9. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
[TBL] [Abstract][Full Text] [Related]
12. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies.
Bay JO; Dhédin N; Goerner M; Vannier JP; Marie-Cardine A; Stamatoullas A; Jouet JP; Yakoub-Agha I; Tabrizi R; Faucher C; Diez-Martin JL; Nunez G; Parody R; Milpied N; Espérou H; Garban F; Galambrun C; Kwiatkovski F; Darlavoix I; Zinaï A; Fischer A; Michallet M; Vernant JP
Transplantation; 2005 Sep; 80(6):782-8. PubMed ID: 16210965
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.
Dotoli GM; De Santis GC; Orellana MD; de Lima Prata K; Caruso SR; Fernandes TR; Rensi Colturato VA; Kondo AT; Hamerschlak N; Simões BP; Covas DT
Bone Marrow Transplant; 2017 Jun; 52(6):859-862. PubMed ID: 28287644
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of TNF-alpha, IL-1beta and IFN-gamma levels at early phase after allogeneic hematopoietic stem cell transplantation].
Gao HL; Sun AN; Han Y; Zhang W; Hu XH; Wu DP; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1321-5. PubMed ID: 19840475
[TBL] [Abstract][Full Text] [Related]
17. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
[TBL] [Abstract][Full Text] [Related]
18. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
Zhao L; Chen S; Yang P; Cao H; Li L
Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
[TBL] [Abstract][Full Text] [Related]
19. [Changes of IL-2, IL-8, IL-10 and TNF-alpha levels in sera of patients with acute graft-versus-host disease].
Wang SH; Da WM; Jin HJ; Jing Y; Yan GT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):755-8. PubMed ID: 16928315
[TBL] [Abstract][Full Text] [Related]
20. High expression of heme oxygenase-1 in target organs may attenuate acute graft-versus-host disease through regulation of immune balance of TH17/Treg.
Yu M; Wang J; Fang Q; Liu P; Chen S; Zhe N; Lin X; Zhang Y; Zhao J; Zhou Z
Transpl Immunol; 2016 Jul; 37():10-17. PubMed ID: 27168057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]